CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

KalVista's sebetralstat shows strong phase 3 results for HAE, but financial concerns and competition make investing cautious. Click here to read more.

Astria Therapeutics' STAR-0215 offers revolutionary HAE treatment with superior results and minimal risks. Click here to find ...

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, is excited to announce the formation of its Scientific ...

Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously ...

About ORLADEYO ® (berotralstat) ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

Research Triangle Park, North Carolina Tuesday, November 19, 2024, 16:00 Hrs [IST] ...

Plasma kallikrein is a protease that cleaves high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin. This potent vasodilator increases vascular permeability ...

including KalVista Pharma's recently filed oral plasma kallikrein inhibitor sebetralstat. The lead investigator in the phase 2 trial, Danny Cohn of Amsterdam University Medical Center in the ...

Quest Partners LLC grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 180.8% during the ...

导读缺血性脑卒中（IS）是脑卒中最常见的类型，具有高发病率、高致残率、高死亡率、高复发率、高经济负担五大特点，严重影响患者的生活质量1。组织激肽释放酶（TK）是一种重要的内源性心脑血管保护因子，既往研究显示，外源性TK可以促进脑血流，改善神经功能障碍 ...

There are five broad categories consistently associated with salt sensitivity. These include demographic factors, racial and social factors, renal function factors, hormonal factors, and dietary ...